Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nonivamide→

Nonivamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2444-46-4
Molecular formula
C17H27NO3
Molecular weight
293.4 g/mol
Drug class
Capsaicinoid analoguetopical TRPV1 agonist counterirritant
Mechanism of action
Activates transient receptor potential vanilloid 1 (TRPV1) channels on cutaneous sensory neurons, initially producing warmth and irritation and then reducing nociceptive signalling through reversible desensitisation of sensory nerve endings.
Indications / reported uses
  • Topical counterirritant in products intended for temporary relief of minor muscular and joint aches, where authorised.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=nonivamide · https://www.ncbi.nlm.nih.gov/mesh/?term=nonivamide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nonivamide Environmental Risk Assessment (ERA) (the Nonivamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.